The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese (OGSG1001).
Koichi Taira
No relevant relationships to disclose
Motoki Yoshida
No relevant relationships to disclose
Naotoshi Sugimoto
No relevant relationships to disclose
Takayuki Kii
No relevant relationships to disclose
Shin Kuwakado
No relevant relationships to disclose
Mutsumi Fukunaga
No relevant relationships to disclose
Hiroko Hasegawa
No relevant relationships to disclose
Takeshi Kato
No relevant relationships to disclose
Yasuhiro Miyake
No relevant relationships to disclose
Taishi Hata
No relevant relationships to disclose
Yukihiko Tokunaga
No relevant relationships to disclose
Koji Takeda
No relevant relationships to disclose
Haruko Daga
No relevant relationships to disclose
Tetsuhiro Yoshinami
No relevant relationships to disclose
Toshio Shimokawa
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Yukinori Kurokawa
No relevant relationships to disclose
Taroh Satoh
No relevant relationships to disclose
Toshimasa Tsujinaka
No relevant relationships to disclose
Hiroshi Furukawa
No relevant relationships to disclose